Testing effectiveness (Phase 2)Ended earlyNCT00811590What this trial is testingPilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers SyndromeWho this might be right forPeutz-Jeghers Syndrome University of Utah 3
Not applicableUnknownNCT03129724What this trial is testingRetrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - AxitinibWho this might be right forKidney Neoplasms University Hospital, Strasbourg, France 100
Testing effectiveness (Phase 2)Study completedNCT00529802What this trial is testingExploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell CancerWho this might be right forCarcinoma, Renal Cell University of Chicago 60
Early research (Phase 1)Study completedNCT00999882What this trial is testingSafety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer PatientsWho this might be right forCancerAdvanced Hepatocellular Carcinoma AstraZeneca 26
Not applicableActive Not RecruitingNCT04542733What this trial is testingThe Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus and Leflunomide in Treatment of BK Virus Infection in Kidney Transplantation RecipientWho this might be right forKidney Transplant InfectionBK Virus Infection King Chulalongkorn Memorial Hospital 50
Early research (Phase 1)Study completedNCT01445106What this trial is testingA Phase I Trial of Nelfinavir (Viracept ) in Adults With Solid TumorsWho this might be right forSolid Tumors National Cancer Institute (NCI) 28
Testing effectiveness (Phase 2)Study completedNCT02019693What this trial is testingThe MET Kinase Inhibitor INC280 in Papillary Renal Cell CancerWho this might be right forKidney Cancer National Cancer Institute (NCI) 20
Early research (Phase 1)Study completedNCT00891696What this trial is testingNutritional and Contractile Regulation of Muscle GrowthWho this might be right forSarcopenia The University of Texas Medical Branch, Galveston 144
Testing effectiveness (Phase 2)Ended earlyNCT02023905What this trial is testingEverolimus With and Without Temozolomide in Adult Low Grade GliomaWho this might be right forLow Grade GliomaWorld Health Organization (WHO) Grade II AstrocytomasOligodendrogliomas+1 more University of California, San Francisco 27
Testing effectiveness (Phase 2)Ended earlyNCT02920450What this trial is testingStudy of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)Who this might be right forNon-Small Cell Lung Cancer University of Florida 3
Not applicableLooking for participantsNCT06053671What this trial is testingMos-FED (Mosaicism in Focal Epilepsy Cortical Dysplasia Tissue)Who this might be right forFocal Cortical DysplasiaEpilepsy King's College Hospital NHS Trust 60
Early research (Phase 1)WithdrawnNCT01194193What this trial is testingPreliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced TumoursWho this might be right forCancerAdvanced Solid TumoursLymphomas AstraZeneca 63
Testing effectiveness (Phase 2)Study completedNCT05835999What this trial is testingEverolimus Aging StudyWho this might be right forAgingInsulin Resistance University of Wisconsin, Madison 106
Early research (Phase 1)WithdrawnNCT02833506What this trial is testingSirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerWho this might be right forRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma+18 more Roswell Park Cancer Institute
Not applicableStudy completedNCT03091465What this trial is testingValidation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With PazopanibWho this might be right forMetastatic Renal Cell Carcinoma Spanish Oncology Genito-Urinary Group 530
Testing effectiveness (Phase 2)Study completedNCT02201212What this trial is testingEverolimus for Cancer With TSC1 or TSC2 MutationWho this might be right forTSC1TSC2Tuberous Sclerosis Complex+1 more Dana-Farber Cancer Institute 30
Early research (Phase 1)Ended earlyNCT03333694What this trial is testingSafety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)Who this might be right forCutaneous Squamous Cell Carcinoma in Situ (CSCCis) Novartis Pharmaceuticals 40
Testing effectiveness (Phase 2)Study completedNCT00632268What this trial is testingLow-dose RAD001(Everolimus) Plus Cisplatin-HDFL Chemotherapy for the First-line Treatment of Advanced Gastric CancerWho this might be right forMetastatic Gastric Cancer National Taiwan University Hospital 40
Testing effectiveness (Phase 2)Ended earlyNCT00926107What this trial is testingStudy of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only RelapseWho this might be right forOvarian Cancer Hellenic Cooperative Oncology Group 9
Early research (Phase 1)Study completedNCT01316809What this trial is testingAZD8055 for Adults With Recurrent GliomasWho this might be right forGlioblastoma MultiformeAnaplastic AstrocytomaAnaplastic Oligodendroglioma+2 more National Cancer Institute (NCI) 22